A Multi-Center, Open-Label, Two-Period Cross-Over, Patient-Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox) Tablets in Thalassemia Patients With Inadequate Response to Standard Chelation Therapy
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox
- Indications Thalassaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors DisperSol Technologies
- 11 Nov 2019 Planned initiation date changed from 20 Aug 2018 to 20 Aug 2019.
- 07 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 07 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.